Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer's Disease and Related Dementias.

Psychedelic drugs are not currently offered to people with Alzheimer's disease and related dementias, but interest is growing in using them to treat underlying causes and psychiatric symptoms. This paper proposes a research agenda for examining the ethics of psychedelic medicine and research involving persons with AD/ADRD. It offers preliminary analyses of six ethical issues: the impact of psychedelics on autonomy and consent; the effect of "ego dissolution" on those experiencing a pathology of self; how psychedelics might affect caregiving; the potential exploitation of patient desperation; institutional review boards' orientation to psychedelic research; and methods to reduce inequity. These issues are magnified for AD/ADRD but also relevant to other clinical populations.

Study at a glance

Abstract

In this paper, we examine the case of psychedelic medicine for Alzheimer's disease and related dementias (AD/ADRD). These "mind-altering" drugs are not currently offered as treatments to persons with AD/ADRD, though there is growing interest in their use to treat underlying causes and associated psychiatric symptoms. We present a research agenda for examining the ethics of psychedelic medicine and research involving persons living with AD/ADRD, and offer preliminary analyses of six ethical issues: the impact of psychedelics on autonomy and consent; the impact of "ego dissolution" on persons experiencing a pathology of self; how psychedelics might impact caregiving; the potential exploitation of patient desperation; institutional review boards' orientation to psychedelic research; and methods to mitigate inequity. These ethical issues are magnified for AD/ADRD but bear broader relevance to psychedelic medicine and research in other clinical populations.